title: Resveratrol shows neuronal and vascular-protective effects in older, obese, streptozotocin-induced diabetic rats.
abstract: Diabetes-induced CVD is the most significant complication of prolonged hyperglycaemia. The aim of this study was to determine whether resveratrol, a polyphenol antioxidant compound, when administered at a dose that can be reasonably obtained through supplementation could prevent the development of cardiovascular complications in older, obese, diabetic rats. Diabetes was induced in 6-month old, obese, male Wistar rats via a single intravenous dose of streptozotocin (65 mg/kg). Randomly selected animals were administered resveratrol (2 mg/kg) via oral gavage daily for 8 weeks. Body weights, blood glucose levels, food intake and water consumption were monitored, and assessments of vascular reactivity, tactile allodynia and left ventricular function were performed. Resveratrol therapy significantly improved tactile allodynia and vascular contractile functionality in diabetic rats (P<0·05). There were no significant changes in standardised vasorelaxation responses, plasma glucose concentrations, water consumption, body weight, left ventricular hypertrophy, kidney hypertrophy, heart rate or left ventricular compliance with resveratrol administration. Resveratrol-mediated improvements in vascular and nerve function in old, obese, diabetic rats were associated with its reported antioxidant effects. Resveratrol did not improve cardiac function nor mitigate the classic clinical symptoms of diabetes mellitus (i.e. hyperglycaemia, polydypsia and a failure to thrive). This suggests that supplementation with resveratrol at a dose achievable with commercially available supplements would not produce significant cardioprotective effects in people with diabetes mellitus.
authors.affiliation: School of Medical and Applied Sciences,Central Queensland University Australia,Bruce Highway,North Rockhampton,Qld 4701,Australia.
authors.forename: Hnin Ei
authors.initials: HE
authors.lastname: Phyu
authors.affiliation: School of Medical and Applied Sciences,Central Queensland University Australia,Bruce Highway,North Rockhampton,Qld 4701,Australia.
authors.forename: Jordon Candice
authors.initials: JC
authors.lastname: Irwin
authors.affiliation: School of Medical and Applied Sciences,Central Queensland University Australia,Bruce Highway,North Rockhampton,Qld 4701,Australia.
authors.forename: Rebecca Kate
authors.initials: RK
authors.lastname: Vella
authors.affiliation: School of Medical and Applied Sciences,Central Queensland University Australia,Bruce Highway,North Rockhampton,Qld 4701,Australia.
authors.forename: Andrew Stuart
authors.initials: AS
authors.lastname: Fenning
mesh_terms: D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000502:physiology; D006930:Hyperalgesia / Q000188:drug therapy; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009420:Nervous System / Q000187:drug effects*; D009765:Obesity / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D010936:Plant Extracts / Q000494:pharmacology* / Q000627:therapeutic use; D059808:Polyphenols / Q000494:pharmacology / Q000627:therapeutic use; D011897:Random Allocation; D017208:Rats, Wistar; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000700:Analgesics; D000975:Antioxidants; D010936:Plant Extracts; D059808:Polyphenols; D013267:Stilbenes; D000077185:Resveratrol
keywords: Age; DM diabetes mellitus; Obesity; Res resveratrol; Resveratrol; SBP systolic blood pressure; STZ streptozotocin; STZ+Res streptozotocin-induced diabetic rats treated with resveratrol; Streptozotocin rats; Type 1 diabetes